Till Baernighausen, M.D.,Ph.D., Sc.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anti-HIV Agents | 6 | 2023 | 4573 | 0.470 |
Why?
|
HIV Infections | 11 | 2023 | 17569 | 0.400 |
Why?
|
Anti-Retroviral Agents | 2 | 2011 | 1789 | 0.370 |
Why?
|
Haemophilus influenzae type b | 1 | 2010 | 16 | 0.370 |
Why?
|
Haemophilus Vaccines | 1 | 2010 | 71 | 0.360 |
Why?
|
Haemophilus Infections | 1 | 2010 | 94 | 0.360 |
Why?
|
Evaluation Studies as Topic | 1 | 2012 | 1625 | 0.340 |
Why?
|
Rural Health Services | 2 | 2010 | 394 | 0.310 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2012 | 1903 | 0.310 |
Why?
|
Burkina Faso | 6 | 2023 | 88 | 0.290 |
Why?
|
Physician Incentive Plans | 1 | 2009 | 165 | 0.290 |
Why?
|
Health Services Accessibility | 4 | 2022 | 5520 | 0.280 |
Why?
|
Health Personnel | 4 | 2022 | 3387 | 0.280 |
Why?
|
Medically Underserved Area | 1 | 2009 | 268 | 0.270 |
Why?
|
Program Evaluation | 2 | 2012 | 2506 | 0.260 |
Why?
|
Delivery of Health Care | 4 | 2023 | 5366 | 0.250 |
Why?
|
Financing, Personal | 1 | 2007 | 310 | 0.240 |
Why?
|
Health Benefit Plans, Employee | 1 | 2007 | 332 | 0.230 |
Why?
|
Africa South of the Sahara | 3 | 2012 | 752 | 0.220 |
Why?
|
Emigration and Immigration | 2 | 2021 | 406 | 0.210 |
Why?
|
Needs Assessment | 1 | 2008 | 1141 | 0.200 |
Why?
|
Population Surveillance | 1 | 2011 | 2594 | 0.180 |
Why?
|
Technology Assessment, Biomedical | 1 | 2023 | 312 | 0.170 |
Why?
|
Bacillus thuringiensis | 1 | 2019 | 12 | 0.170 |
Why?
|
Fellowships and Scholarships | 1 | 2008 | 1135 | 0.170 |
Why?
|
Pest Control, Biological | 1 | 2019 | 21 | 0.170 |
Why?
|
Medication Adherence | 1 | 2011 | 2187 | 0.170 |
Why?
|
Intention | 1 | 2022 | 347 | 0.160 |
Why?
|
Mental Health | 3 | 2022 | 3275 | 0.160 |
Why?
|
Infant Mortality | 1 | 2024 | 752 | 0.160 |
Why?
|
Mosquito Control | 1 | 2019 | 110 | 0.150 |
Why?
|
Vaccination | 1 | 2010 | 3437 | 0.150 |
Why?
|
Parturition | 1 | 2022 | 454 | 0.150 |
Why?
|
Transients and Migrants | 1 | 2021 | 170 | 0.150 |
Why?
|
Insecticides | 1 | 2019 | 200 | 0.150 |
Why?
|
Anopheles | 1 | 2019 | 193 | 0.140 |
Why?
|
History, 18th Century | 1 | 2017 | 206 | 0.140 |
Why?
|
Ethiopia | 3 | 2022 | 485 | 0.120 |
Why?
|
Activities of Daily Living | 1 | 2024 | 2429 | 0.120 |
Why?
|
Insurance, Health | 1 | 2007 | 2517 | 0.120 |
Why?
|
History, 19th Century | 1 | 2017 | 714 | 0.120 |
Why?
|
Social Stigma | 1 | 2021 | 788 | 0.120 |
Why?
|
Nigeria | 3 | 2022 | 781 | 0.120 |
Why?
|
Tanzania | 3 | 2022 | 1407 | 0.100 |
Why?
|
Poverty | 1 | 2023 | 2720 | 0.090 |
Why?
|
Research Design | 2 | 2017 | 6212 | 0.090 |
Why?
|
Pandemics | 4 | 2023 | 8750 | 0.090 |
Why?
|
Public Health | 1 | 2024 | 2682 | 0.090 |
Why?
|
Cost-Benefit Analysis | 3 | 2023 | 5536 | 0.090 |
Why?
|
Humans | 30 | 2024 | 767998 | 0.090 |
Why?
|
Tuberculosis | 2 | 2015 | 2029 | 0.080 |
Why?
|
History, 20th Century | 1 | 2017 | 2765 | 0.080 |
Why?
|
Ambulatory Care Facilities | 1 | 2015 | 939 | 0.080 |
Why?
|
Models, Econometric | 1 | 2008 | 215 | 0.080 |
Why?
|
Telephone | 2 | 2021 | 629 | 0.070 |
Why?
|
Costs and Cost Analysis | 1 | 2012 | 1666 | 0.070 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2021 | 4055 | 0.070 |
Why?
|
Rural Health | 1 | 2007 | 302 | 0.060 |
Why?
|
Sentinel Surveillance | 1 | 2007 | 292 | 0.060 |
Why?
|
South Africa | 3 | 2022 | 1873 | 0.060 |
Why?
|
Family Planning Services | 1 | 2007 | 279 | 0.060 |
Why?
|
Angola | 1 | 2023 | 18 | 0.060 |
Why?
|
Contraception | 1 | 2007 | 362 | 0.060 |
Why?
|
Liberia | 1 | 2024 | 176 | 0.050 |
Why?
|
Renal Insufficiency | 1 | 2009 | 812 | 0.050 |
Why?
|
Lesotho | 1 | 2023 | 76 | 0.050 |
Why?
|
Monte Carlo Method | 1 | 2008 | 1260 | 0.050 |
Why?
|
Hypertension | 1 | 2022 | 8616 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 1 | 2008 | 1741 | 0.050 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2010 | 951 | 0.050 |
Why?
|
Child Mortality | 1 | 2024 | 204 | 0.050 |
Why?
|
Biomedical Research | 1 | 2017 | 3464 | 0.050 |
Why?
|
England | 1 | 2023 | 533 | 0.050 |
Why?
|
Prevalence | 4 | 2024 | 15867 | 0.050 |
Why?
|
China | 1 | 2007 | 2395 | 0.050 |
Why?
|
Child | 6 | 2024 | 80905 | 0.050 |
Why?
|
Germany | 1 | 2023 | 882 | 0.040 |
Why?
|
Glomerular Filtration Rate | 1 | 2009 | 2227 | 0.040 |
Why?
|
Female | 14 | 2024 | 397102 | 0.040 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2008 | 2204 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2022 | 639 | 0.040 |
Why?
|
Poverty Areas | 1 | 2021 | 268 | 0.040 |
Why?
|
Bangladesh | 1 | 2021 | 742 | 0.040 |
Why?
|
Sexual Partners | 1 | 2023 | 805 | 0.040 |
Why?
|
Europe | 1 | 2024 | 3438 | 0.040 |
Why?
|
Larva | 1 | 2019 | 515 | 0.040 |
Why?
|
Health Services | 1 | 2022 | 755 | 0.040 |
Why?
|
Patient Care Team | 1 | 2008 | 2521 | 0.040 |
Why?
|
AIDS Serodiagnosis | 2 | 2010 | 220 | 0.040 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 26377 | 0.040 |
Why?
|
Child, Preschool | 3 | 2022 | 42665 | 0.030 |
Why?
|
Child Health Services | 1 | 2021 | 645 | 0.030 |
Why?
|
Maternal Health Services | 1 | 2021 | 472 | 0.030 |
Why?
|
Health Care Costs | 1 | 2008 | 3240 | 0.030 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2007 | 2185 | 0.030 |
Why?
|
Male | 9 | 2024 | 364638 | 0.030 |
Why?
|
Computer Simulation | 1 | 2008 | 6285 | 0.030 |
Why?
|
Educational Status | 1 | 2022 | 2514 | 0.030 |
Why?
|
Patient Acceptance of Health Care | 2 | 2023 | 3231 | 0.030 |
Why?
|
Alkynes | 1 | 2015 | 326 | 0.030 |
Why?
|
Nevirapine | 1 | 2015 | 273 | 0.030 |
Why?
|
Adult | 7 | 2023 | 223577 | 0.030 |
Why?
|
Cyclopropanes | 1 | 2015 | 436 | 0.030 |
Why?
|
Lamivudine | 1 | 2015 | 367 | 0.030 |
Why?
|
Motivation | 1 | 2023 | 2020 | 0.030 |
Why?
|
Benzoxazines | 1 | 2015 | 320 | 0.030 |
Why?
|
Primary Health Care | 1 | 2010 | 4746 | 0.030 |
Why?
|
Urban Population | 1 | 2021 | 2045 | 0.030 |
Why?
|
Zidovudine | 1 | 2015 | 625 | 0.030 |
Why?
|
Infant | 2 | 2015 | 36533 | 0.030 |
Why?
|
Pregnancy | 3 | 2022 | 30244 | 0.020 |
Why?
|
Income | 1 | 2021 | 1878 | 0.020 |
Why?
|
Mothers | 1 | 2022 | 2209 | 0.020 |
Why?
|
Health Behavior | 1 | 2022 | 2650 | 0.020 |
Why?
|
Adolescent | 4 | 2023 | 89154 | 0.020 |
Why?
|
Qualitative Research | 1 | 2021 | 3141 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2023 | 7851 | 0.020 |
Why?
|
Age Distribution | 1 | 2015 | 2871 | 0.020 |
Why?
|
Decision Making | 1 | 2023 | 3953 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2015 | 2596 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2024 | 14785 | 0.020 |
Why?
|
Age Factors | 1 | 2024 | 18405 | 0.020 |
Why?
|
Selection Bias | 1 | 2007 | 360 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2012 | 65360 | 0.020 |
Why?
|
Aged | 3 | 2024 | 171453 | 0.020 |
Why?
|
Middle Aged | 4 | 2024 | 223422 | 0.020 |
Why?
|
Diet | 1 | 2023 | 8087 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 10396 | 0.020 |
Why?
|
Linear Models | 1 | 2015 | 5883 | 0.010 |
Why?
|
Young Adult | 2 | 2021 | 60050 | 0.010 |
Why?
|
Retrospective Studies | 3 | 2024 | 81748 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 26418 | 0.010 |
Why?
|
Risk Factors | 2 | 2023 | 74938 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2007 | 2731 | 0.010 |
Why?
|
Comorbidity | 1 | 2015 | 10590 | 0.010 |
Why?
|
Prenatal Care | 1 | 2007 | 1160 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2024 | 59600 | 0.010 |
Why?
|
Odds Ratio | 1 | 2009 | 9667 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2015 | 15944 | 0.010 |
Why?
|
Logistic Models | 1 | 2009 | 13289 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2009 | 14718 | 0.010 |
Why?
|
Animals | 1 | 2019 | 169225 | 0.000 |
Why?
|
Prospective Studies | 1 | 2009 | 54921 | 0.000 |
Why?
|